Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach

2017109 citationsJournal Articlehybrid Open Access

Authors

Yukinori Kurokawa · The University of Osaka

Han‐Kwang Yang · Seoul National University Hospital

Haruhiko Cho · Kanagawa Prefectural Hospital Organization

Min‐Hee Ryu · University of Ulsan

Toru Masuzawa · Osaka Police Hospital

Sook Ryun Park · Ulsan College

Sohei Matsumoto ·

Abstract

Neoadjuvant imatinib treatment for 6-9 months is a promising treatment for large gastric GISTs, allowing a high R0 resection rate with acceptable toxicity.

Topics & Keywords

Gastrointestinal Tumor Research and Treatment Gastric Cancer Management and Outcomes Gastrointestinal disorders and treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: British Journal of Cancer

Volume 117, Issue 1, pp. 25-32

DOI: 10.1038/bjc.2017.144

Field-Weighted Citation Impact: 5.53